UNDERSTANDING RESPONSE EVALUATION CRITERIA IN SOLID TUMORS (RECIST): A CLINICAL TRIAL NURSE'S PERSPECTIVE.

2.50
Hdl Handle:
http://hdl.handle.net/10755/165217
Category:
Abstract
Type:
Presentation
Title:
UNDERSTANDING RESPONSE EVALUATION CRITERIA IN SOLID TUMORS (RECIST): A CLINICAL TRIAL NURSE'S PERSPECTIVE.
Author(s):
DelaCruz, Anthony; Curley, Tracy
Author Details:
Anthony DelaCruz, RN OCN, Research Nurse, MSKCC, New York, New York, USA, email: delacrua@mskcc.org; Tracy Curley, RN, OCN, MSKCC
Abstract:
Determining objective tumor responses associated with the administration of new anticancer agents is crucial in evaluating the efficacy of a drug. RECIST (response evaluation criteria in solid tumors), is a widely employed method to assess changes in tumor size in response to treatment. This is of particular interest to the clinical trials nurse and for patients considering a clinical trial. Objective tumor responses determine whether the agent/regimen demonstrates sufficiently encouraging results to warrant further testing. It is essential that nurses understand RECIST so they may counsel patients and families and assist in the decision making process. The need for more uniform reporting of a therapeutic response in clinical trials is essential. Understanding the guidelines, definitions, assumptions and purposes of tumor response criteria is a critical part of the role of the nurse involved in clinical trials and applicable to all oncology nursing practices. Standardized response criteria are critical for directing individual patient care, evaluating new therapies, and communicating risks to family and patients. RECIST allows for investigators to speak the same language when they are reporting study results. It enables the nurse to clearly and objectively discuss individual results with a patient. This presentation will inform nurses of the eligibility, methods of measurements, and specific response criteria. Limitations to the current guidelines which have been identified in recent years will be discussed. Tools that may be used will be demonstrated. RECIST guidelines may lead to more uniform reporting of outcomes of clinical trials and facilitate the way nurses communicate treatment responses. Understanding these guidelines will also allow the nurse to recognize problems with the current system given that tumor cells may react differently to new drugs and new imaging techniques allow more accurate measurements of tumor density. This knowledge will empower nurses to objectively discuss treatment effects with their peers, investigators, family members and patients. Understanding RECIST will enable nurses to use standard terminology when reporting treatment responses and aid in their communication with patients.
Repository Posting Date:
27-Oct-2011
Date of Publication:
27-Oct-2011
Conference Date:
2007
Conference Name:
32nd Annual Oncology Nursing Society Congress
Conference Host:
Oncology Nursing Society
Conference Location:
Las Vegas, Nevada, USA
Note:
This is an abstract-only submission. If the author has submitted a full-text item based on this abstract, you may find it by browsing the Virginia Henderson Global Nursing e-Repository by author. If author contact information is available in this abstract, please feel free to contact him or her with your queries regarding this submission. Alternatively, please contact the conference host, journal, or publisher (according to the circumstance) for further details regarding this item. If a citation is listed in this record, the item has been published and is available via open-access avenues or a journal/database subscription. Contact your library for assistance in obtaining the as-published article.

Full metadata record

DC FieldValue Language
dc.type.categoryAbstracten_US
dc.typePresentationen_GB
dc.titleUNDERSTANDING RESPONSE EVALUATION CRITERIA IN SOLID TUMORS (RECIST): A CLINICAL TRIAL NURSE'S PERSPECTIVE.en_GB
dc.contributor.authorDelaCruz, Anthonyen_US
dc.contributor.authorCurley, Tracyen_US
dc.author.detailsAnthony DelaCruz, RN OCN, Research Nurse, MSKCC, New York, New York, USA, email: delacrua@mskcc.org; Tracy Curley, RN, OCN, MSKCCen_US
dc.identifier.urihttp://hdl.handle.net/10755/165217-
dc.description.abstractDetermining objective tumor responses associated with the administration of new anticancer agents is crucial in evaluating the efficacy of a drug. RECIST (response evaluation criteria in solid tumors), is a widely employed method to assess changes in tumor size in response to treatment. This is of particular interest to the clinical trials nurse and for patients considering a clinical trial. Objective tumor responses determine whether the agent/regimen demonstrates sufficiently encouraging results to warrant further testing. It is essential that nurses understand RECIST so they may counsel patients and families and assist in the decision making process. The need for more uniform reporting of a therapeutic response in clinical trials is essential. Understanding the guidelines, definitions, assumptions and purposes of tumor response criteria is a critical part of the role of the nurse involved in clinical trials and applicable to all oncology nursing practices. Standardized response criteria are critical for directing individual patient care, evaluating new therapies, and communicating risks to family and patients. RECIST allows for investigators to speak the same language when they are reporting study results. It enables the nurse to clearly and objectively discuss individual results with a patient. This presentation will inform nurses of the eligibility, methods of measurements, and specific response criteria. Limitations to the current guidelines which have been identified in recent years will be discussed. Tools that may be used will be demonstrated. RECIST guidelines may lead to more uniform reporting of outcomes of clinical trials and facilitate the way nurses communicate treatment responses. Understanding these guidelines will also allow the nurse to recognize problems with the current system given that tumor cells may react differently to new drugs and new imaging techniques allow more accurate measurements of tumor density. This knowledge will empower nurses to objectively discuss treatment effects with their peers, investigators, family members and patients. Understanding RECIST will enable nurses to use standard terminology when reporting treatment responses and aid in their communication with patients.en_GB
dc.date.available2011-10-27T12:14:35Z-
dc.date.issued2011-10-27en_GB
dc.date.accessioned2011-10-27T12:14:35Z-
dc.conference.date2007en_US
dc.conference.name32nd Annual Oncology Nursing Society Congressen_US
dc.conference.hostOncology Nursing Societyen_US
dc.conference.locationLas Vegas, Nevada, USAen_US
dc.description.noteThis is an abstract-only submission. If the author has submitted a full-text item based on this abstract, you may find it by browsing the Virginia Henderson Global Nursing e-Repository by author. If author contact information is available in this abstract, please feel free to contact him or her with your queries regarding this submission. Alternatively, please contact the conference host, journal, or publisher (according to the circumstance) for further details regarding this item. If a citation is listed in this record, the item has been published and is available via open-access avenues or a journal/database subscription. Contact your library for assistance in obtaining the as-published article.-
All Items in this repository are protected by copyright, with all rights reserved, unless otherwise indicated.